Press Releases - 2018-09

Displaying 1 - 5 of 5 results
Collapse Filters

Click here for Archived Press Releases prior to 2016

Expand Filters         +
September 27, 2018

Former Miami-Dade County resident sentenced to more than 8 years in prison for bank fraud and money laundering schemes

MIAMI - A former Miami-Dade County resident was sentenced to 97 months in prison, to be followed by five years of supervised release, and was ordered to pay $722,000 in restitution for his roles in bank fraud and money laundering schemes.

Jose Orlando Sanchez Cristancho, a.k.a. Orlando Sanchez, 57, a citizen of Colombia who formerly resided in Miami-Dade County, previously pled guilty to one count of conspiracy to commit wire and bank fraud. 

September 27, 2018

Former Colombian councilman sentenced to fourteen years in prison for conspiring to traffic more than a thousand kilograms of cocaine

TAMPA, Fla., - Aureliano Cuero-Cuero aka "Chavo," 38, of Mosquera, Nariño, Colombia was sentenced to 14 years in federal prison for conspiring to distribute cocaine on board vessels subject to the jurisdiction of the United States. Cuero-Cuero pleaded guilty on May 23, 2018. According to court records, Cuero-Cuero was an elected city council member in Mosquera, Nariño, Colombia at the time of his indictment in 2016.

September 27, 2018

Washington man sentenced to over 12 years in prison for meth offense

MISSOULA, Mont., - Salomon Mejia Preciado, a 36-year-old resident of Yakima, Washington, was sentenced today to 151 months in prison to be followed by 5 years of supervised release.  Preciado pleaded guilty to conspiracy to distribute methamphetamine. Preciado is a former federal felon and was prosecuted in the Eastern District of Washington and sentenced in 2003 to ten years in prison.  U.S. District Judge Donald W. Molloy handed down the sentence. 

September 27, 2018

FDA-approved drug Epidiolex placed in schedule V of Controlled Substance Act

WASHINGTON - The Department of Justice and Drug Enforcement Administration today announced that Epidiolex, the newly approved medication by the Food & Drug Administration, is being placed in schedule V of the Controlled Substances Act, the least restrictive schedule of the CSA.

In June 2018, the FDA announced it approved Epidiolex for the treatment of seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome, in patients two years of age and older.

DEA US Badge
United States Drug Enforcement Administration is an official site of the U.S. Department of Justice